Talphera (NASDAQ:TLPH – Get Free Report) is expected to be issuing its Q2 2026 results after the market closes on Thursday, August 13th. Analysts expect Talphera to post earnings of ($0.07) per share for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 4:30 PM ET.
Talphera (NASDAQ:TLPH – Get Free Report) last issued its earnings results on Wednesday, May 13th. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.03. On average, analysts expect Talphera to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.
Talphera Price Performance
Shares of NASDAQ TLPH opened at $1.41 on Tuesday. The business has a 50-day moving average of $1.15 and a two-hundred day moving average of $0.95. The company has a market capitalization of $73.18 million, a price-to-earnings ratio of -4.55 and a beta of 0.69. Talphera has a 1 year low of $0.40 and a 1 year high of $1.57.
Hedge Funds Weigh In On Talphera
Analyst Ratings Changes
Several analysts have recently weighed in on TLPH shares. Weiss Ratings restated a “sell (d-)” rating on shares of Talphera in a research report on Friday, July 17th. Zacks Research upgraded Talphera to a “hold” rating in a research note on Monday, June 8th. HC Wainwright started coverage on shares of Talphera in a research note on Friday, June 5th. They set a “buy” rating and a $3.00 price target on the stock. Westpark Capital initiated coverage on Talphera in a report on Thursday, April 30th. They set a “buy” rating and a $3.00 price objective on the stock. Finally, Wall Street Zen upgraded shares of Talphera to a “hold” rating in a research report on Saturday. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $3.00.
Get Our Latest Stock Report on Talphera
About Talphera
Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.
Read More
- Five stocks we like better than Talphera
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
- First Solar’s Profit Engine Faces a New Policy Test in Washington
Receive News & Ratings for Talphera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talphera and related companies with MarketBeat.com's FREE daily email newsletter.
